LifeVantage Corp. Hits New 52-Week Low at $9.23 Amid Market Struggles

LifeVantage Corp., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 9.23 as of October 7, 2025. This decline marks a significant point in the company's recent performance trajectory, especially considering its 52-week high was recorded at USD 27.38.
Over the past year, LifeVantage has experienced a return of -16.58%, contrasting sharply with the S&P 500's performance of 17.2%. Despite this downturn, the company has shown resilience in certain financial metrics. For instance, it reported a net profit of USD 5.43 million for the first half of the year, reflecting an impressive growth rate of 83.16%. Additionally, the return on equity (ROE) stands at a robust 28.30%, indicating effective management efficiency.

LifeVantage's market capitalization is currently at USD 145 million, with a price-to-earnings (P/E) ratio of 17.00. The company also boasts a dividend yield of 1.84% and a low debt-to-equity ratio of -0.53, suggesting a solid financial foundation. However, the long-term growth outlook appears subdued, with operating profit declining at an annual rate of -5.22% over the past five years.